Factor IX Depleted Human Plasma

<strong>Factor IX Depleted Human Plasma</strong>_x000D_ <strong>Catalog number:</strong> B2012835_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 mL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Plasma_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> FIX Deficient Plasma_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Mannucci PM. Hemophilia therapy: the future has begun Haematologica. 2020 Mar;105(3):545-553._x000D_ 2: Winter WE, Flax SD, Harris NS. Coagulation Testing in the Core Laboratory Lab Med. 2017 Nov 8;48(4):295-313._x000D_ 3: Goodall AH, Kemble G, O'Brien DP, Rawlings E, Rotblat F, Russell GC, Janossy G, Tuddenham EG. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody Blood. 1982 Mar;59(3):664-70._x000D_ 4: Hung KL, Meitlis I, Hale M, Chen CY, Singh S, Jackson SW, Miao CH, Khan IF, Rawlings DJ, James RG. Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells Mol Ther. 2018 Feb 7;26(2):456-467._x000D_ 5: Pegg CL, Zacchi LF, Recinos DR, Howard CB, Schulz BL. Identification of novel glycosylation events on human serum-derived factor IX Glycoconj J. 2020 Aug;37(4):471-483._x000D_ 6: Østergaard H, Lund J, Greisen PJ, Kjellev S, Henriksen A, Lorenzen N, Johansson E, Røder G, Rasch MG, Johnsen LB, Egebjerg T, Lund S, Rahbek-Nielsen H, Gandhi PS, Lamberth K, Loftager M, Andersen LM, Bonde AC, Stavenuiter F, Madsen DE, Li X, Holm TL, Ley CD, Thygesen P, Zhu H, Zhou R, Thorn K, Yang Z, Hermit MB, Bjelke JR, Hansen BG, Hilden I. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice Blood. 2021 Oct 7;138(14):1258-1268._x000D_ 7: Mohammed BM, Cheng Q, Matafonov A, Monroe DM, Meijers JCM, Gailani D. Factor XI promotes hemostasis in factor IX-deficient mice J Thromb Haemost. 2018 Oct;16(10):2044-2049._x000D_ 8: Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays J Thromb Haemost. 2020 Jun;18(6):1242-1255._x000D_ 9: Minami H, Nogami K, Yada K, Ogiwara K, Furukawa S, Soeda T, Kitazawa T, Shima M. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro J Thromb Haemost. 2019 Jan;17(1):126-137._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/25929807">10: Sørensen MH, Andersen S, Ezban M. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays Haemophilia. 2015 Nov;21(6):832-6. </a>_x000D_ _x000D_ <strong>Products Related to Factor IX Depleted Human Plasma can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>